News - Onyx Pharmaceuticals


Current filters:

Onyx Pharmaceuticals

Popular Filters

28 to 35 of 35 results

Onyx falls as FDA says no priority review for cancer drug


US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) saw its shares fall 7.1% to $37.76 in early trading…

carfilzomibNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Bayer halts regorafenib trial for colorectal cancer on good Ph III results


USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced…

BayerOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibResearch

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment


US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

Onyx Pharma files NDA for multiple myeloma drug carfilzomib


California, USA-based Onyx Pharmaceuticals (Nasdaq: ONXX) says it has completed the New Drug Application…

carfilzomibNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Executive changes at Onyx Pharma and XOMA


Onyx Pharmaceuticals (Nasdaq: ONXX) has appointed Helen Torley as executive vice president and chief…

ManagementOnyx PharmaceuticalsPharmaceuticalXOMA Corp

Low-dose sorafenib may improve therapy for head and neck cancer, Ohio researchers find


Adding low doses of the targeted agent sorafenib (German drug major Bayer and Onyx’ kidney and liver…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

28 to 35 of 35 results

Back to top